A Vision For Global Growth In Medical Aesthetics
Carrie Strom, newly appointed Global CEO of Hugel Inc., shares her vision to transform the company into a global aesthetics powerhouse with innovative leadership and expanded international presence.
Hugel Inc., a prominent medical aesthetics innovator headquartered in South Korea, has announced the appointment of industry veteran Carrie Strom as its new President and Global Chief Executive Officer. Strom is set to take on the newly created global CEO role starting October 13, 2025, and is also expected to join the company’s Board of Directors upon approval at an upcoming shareholders’ meeting.
The appointment signals a significant move for Hugel, which has been steadily bolstering its global footprint in the medical aesthetics industry. Strom will oversee Hugel’s global executive leadership team, including Daniel Chang, the recently announced head of Hugel Korea.
With a career spanning over two decades, Strom brings impressive credentials to her new role. She previously served as Senior Vice President of AbbVie and Global President of Allergan Aesthetics, where she managed a $5 billion product portfolio that included renowned brands like Botox Cosmetic and Juvéderm. Under her leadership, Allergan Aesthetics operated in over 50 international markets, cementing its position as a key player in the industry. Strom also held pivotal roles at Pfizer earlier in her career, where she gained extensive experience in sales and marketing.
Reflecting on her new position, Strom shared her enthusiasm: “I am honored to join Hugel as the CEO and look forward to working alongside the talented and dedicated employees, operating team, and board of directors. Hugel offers market-leading aesthetic products driven by science and the highest quality, which have always been grounded in Korean beauty standards. My priority is to build on Hugel’s leadership in South Korea and transform it into a global aesthetics powerhouse, raising the bar for how we serve customers and patients around the world.”
Hugel, which launched in 2001, has become a dominant force in the South Korean botulinum toxin market and is the only Korean aesthetics company with regulatory approvals across the U.S., China, and Europe—the three largest global markets. Currently, the company markets its botulinum toxin products, including Botulax® and Letybo®, in 69 countries, while its dermal fillers are available in 53 nations.
“Our Board is thrilled to welcome Carrie Strom to the Hugel family,” said Suk Cha, Chairman of the Hugel Board of Directors. “Ms. Strom is a proven enterprise leader who we are confident will lead Hugel to the next level. Under her leadership, we anticipate significant growth, particularly in the Americas and other vital global markets.”
Hugel’s vision for further expansion aligns with Strom’s trajectory as a leader who understands both the science and strategy underpinning the medical aesthetics space. With subsidiaries in nine countries, including the U.S., Australia, Canada, and China, the company is well-positioned to build on its legacy of innovation, quality, and dedication to customer satisfaction.
Beauty enthusiasts and industry professionals alike can expect significant developments as Hugel accelerates its international ambitions under Strom’s expert guidance. As a pioneer in blending cutting-edge science with the principles of Korean beauty, Hugel’s future seems poised for even greater global impact.
